Doctor profile · Federal record

Dr. Santhosh Ambika, MD

Hematology & Oncology Physician (CMS: Hematology/Oncology) · Hematology (Pathology) Physician · Reno, NV

  • NPI 1174747323
  • Accepts Medicare
  • MIPS 91.6 / 100 · 2023
  • 25 yrs in practice
  • Male
  • Group practice
  • No sanctions

Practice & contact

NPPES Updated May 11, 2026
Primary practice
5423 Reno Corporate Dr.
Reno, NV 895112250
(775) 329-0873
fax (775) 329-1026
Mailing address
5423 Reno Corporate Dr
Reno, NV 895112250

Credentials & registration

NPPES · NUCC
NPI registered
April 2007 — 19 yrs on file
Profile last updated
May 22, 2019
Year of graduation
2001 — 25 yrs since
Specialty taxonomy
207RH0003X — NUCC code
State license (1)
Nevada #16308

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1174747323. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
73,117
Distinct HCPCS
10
Medicare allowed
$2,443,533
HCPCS Description Services Patients Avg allowed
J9271 Injection, pembrolizumab, 1 mg 20,600 25 $54
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj 13,680 16 $48
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) 8,160 12 $0
J9033 Injection, bendamustine hcl (treanda), 1 mg 6,475 11 $14
J0185 Injection, aprepitant, 1 mg 4,420 13 $2
J0897 Injection, denosumab, 1 mg 3,000 19 $23
J0894 Injection, decitabine, 1 mg 2,600 15 $2
J1100 Injection, dexamethasone sodium phosphate, 1 mg 2,266 80 $0
J2469 Injection, palonosetron hcl, 25 mcg 1,700 62 $1
J9041 Injection, bortezomib, 0.1 mg 1,365 11 $5

In context: peer comparison

Among 8 peers in Reno Hematology & Oncology Physician, average services per provider: 1,102. This provider delivers 66× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$22,511
Transactions
64
Manufacturers
15
Payer (manufacturer) Industry Txns Amount
Abbvie INC. 24 $18,197.50
Taiho Oncology, INC. 2 $1,602.54
Daiichi Sankyo INC. 6 $1,350.11
E.R. Squibb & Sons, L.L.C. 4 $110.11
Merck Sharp & Dohme LLC 4 $107.15
Genentech USA, INC. 4 $94.79
Pfizer INC. 4 $78.90
Sobi, INC 2 $77.16
TerSera Therapeutics LLC 2 $65.06
SpringWorks Therapeutics, INC. 2 $58.26
Deciphera Pharmaceuticals INC. 2 $55.07
Astellas Pharma US INC 2 $50.91
Mirati Therapeutics, INC. 2 $49.99
Array Biopharma INC 2 $49.96
Emd Serono, INC. 2 $49.88

By nature of payment

Consulting Fee
$10,535
Compensation for Services Other Than Consulting, Including Serving As Faculty or As A Speaker at A Venue Other Than A Continuing Education Program
$8,250
Food and Beverage
$2,176
Travel and Lodging
$1,534
Education
$16

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
678
Patients
167
Total drug cost
$2,766,384
Drug Type Claims Patients Total cost
Anastrozole Generic 103 36 $3,272
Hydroxyurea Generic 74 18 $2,582
Levothyroxine Sodium Generic 64 14 $443
Acyclovir Generic 51 16 $790
Brukinsa (Zanubrutinib) Brand 48 0 $565,910
Jakafi (Ruxolitinib Phosphate) Brand 47 0 $770,036
Alendronate Sodium Generic 39 11 $557
Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) Brand 39 16 $447
Ibrance (Palbociclib) Brand 35 0 $547,749
Ondansetron Odt (Ondansetron) Brand 35 22 $547

Hospital affiliations

CMS Hospital Compare

Frequently asked questions

Auto-generated from federal data
What is Dr. Santhosh Ambika's medical specialty?
Dr. Santhosh Ambika practices Hematology & Oncology Physician in Reno, NV.
Where does Dr. Santhosh Ambika practice?
Dr. Santhosh Ambika practices at 5423 Reno Corporate Dr., Reno, NV 895112250. Office phone: 7753290873.
What is Dr. Santhosh Ambika's NPI?
Dr. Santhosh Ambika's National Provider Identifier (NPI) is 1174747323, issued by NPPES.
Does Dr. Santhosh Ambika accept Medicare assignment?
Yes. Dr. Santhosh Ambika accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Santhosh Ambika commonly perform?
Top Medicare-reported procedures in 2023: Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS J9144); Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138). Source: CMS Medicare Physician & Other Practitioners file.